Worth Watching: Zimmer Holdings Inc (NYSE:ZBH) Institutional Investors Sentiment Unchanged in Q2 2016

November 25, 2016 - By Richard Conner   ·   0 Comments

Worth Watching: Zimmer Holdings Inc (NYSE:ZBH) Institutional Investors Sentiment Unchanged in  Q2 2016

Sentiment for Zimmer Holdings Inc (NYSE:ZBH)

Zimmer Holdings Inc (NYSE:ZBH) institutional sentiment decreased to 1.02 in Q2 2016. Its down -0.14, from 1.16 in 2016Q1. The ratio dived, as 312 funds increased or opened new stock positions, while 270 reduced and sold holdings in Zimmer Holdings Inc. The funds in our partner’s database now possess: 173.10 million shares, down from 178.73 million shares in 2016Q1. Also, the number of funds holding Zimmer Holdings Inc in their top 10 stock positions increased from 15 to 16 for an increase of 1. Sold All: 51 Reduced: 219 Increased: 240 New Position: 72.

Zimmer Biomet Holdings, Inc., formerly Zimmer Holdings, Inc., is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The company has a market cap of $20.58 billion. The Company’s products and solutions helps treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It has a 57.4 P/E ratio. The Firm manages its activities through three geographic operating divisions: the Americas, consists of the United States and includes other North, Central and South American markets; EMEA, consists of Europe and includes the Middle East and African markets, and Asia Pacific, consists of Japan and includes other Asian and Pacific markets.

Zimmer Biomet Holdings Inc (NYSE:ZBH) has declined 11.99% since April 22, 2016 and is downtrending. It has underperformed by 17.40% the S&P500.

Analysts await Zimmer Biomet Holdings Inc (NYSE:ZBH) to report earnings on January, 26. They expect $2.11 EPS, up 0.96% or $0.02 from last year’s $2.09 per share. ZBH’s profit will be $423.36 million for 12.15 P/E if the $2.11 EPS becomes a reality. After $1.79 actual EPS reported by Zimmer Biomet Holdings Inc for the previous quarter, Wall Street now forecasts 17.88% EPS growth.

According to Zacks Investment Research, “Zimmer Biomet Holdings, Inc. is a musculoskeletal healthcare company. The company design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. Zimmer Biomet Holdings, Inc., formerly known as Zimmer Holdings, Inc., is based in Warsaw, United States.”

Zimmer Biomet Holdings Inc (NYSE:ZBH) Ratings Coverage

Ratings analysis reveals 75% of Zimmer Biomet Holdings’s analysts are positive. Out of 16 Wall Street analysts rating Zimmer Biomet Holdings, 12 give it “Buy”, 1 “Sell” rating, while 3 recommend “Hold”. The lowest target is $105 while the high is $155. The stock’s average target of $130.57 is 27.30% above today’s ($102.57) share price. ZBH was included in 24 notes of analysts from August 27, 2015. The stock of Zimmer Biomet Holdings Inc (NYSE:ZBH) has “Strong Buy” rating given on Tuesday, November 1 by Needham. As per Wednesday, November 4, the company rating was initiated by Sterne Agee CRT. As per Wednesday, May 25, the company rating was upgraded by Argus Research. UBS maintained the stock with “Neutral” rating in Tuesday, August 2 report. The company was downgraded on Tuesday, November 8 by Northcoast. The rating was maintained by RBC Capital Markets with “Outperform” on Monday, November 2. UBS initiated the shares of ZBH in a report on Tuesday, September 22 with “Neutral” rating. Credit Suisse initiated the shares of ZBH in a report on Friday, October 9 with “Outperform” rating. On Thursday, March 17 the stock rating was initiated by Nomura with “Buy”. The firm earned “Overweight” rating on Friday, April 29 by Barclays Capital.

ZBH Company Profile

Zimmer Biomet Holdings, Inc., formerly Zimmer Holdings, Inc., incorporated on January 12, 2001, is engaged in designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma (S.E.T.) products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company’s products and solutions helps treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. The Firm manages its activities through three geographic operating divisions: the Americas, comprising principally of the United States and includes other North, Central and South American markets; EMEA, comprising of principally of Europe and includes the Middle East and African markets, and Asia Pacific, comprising primarily of Japan and includes other Asian and Pacific markets. The Company’s four product category divisions include Americas Spine, Bone Healing Craniomaxillofacial and Thoracic (CMF) and Dental.

More notable recent Zimmer Biomet Holdings Inc (NYSE:ZBH) news were published by: Forbes.com which released: “Zimmer Biomet Holdings Becomes Oversold (ZBH)” on November 22, 2016, also Wsj.com with their article: “Zimmer Biomet Cuts Forecasts” published on October 31, 2016, Prnewswire.com published: “ZIMMER BIOMET (ZBH) Alert: Shareholder Rights Law Firm Johnson & Weaver, LLP …” on November 02, 2016. More interesting news about Zimmer Biomet Holdings Inc (NYSE:ZBH) were released by: Reuters.com and their article: “BRIEF-Seikagaku signs exclusive distribution agreement with Zimmer Biomet …” published on November 08, 2016 as well as Prnewswire.com‘s news article titled: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” with publication date: November 01, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Richard Conner

Tags: , ,


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>